PBF Energy Inc. filed a current report on September 14, 2026, disclosing that its indirect subsidiary PBF Holding Company LLC and PBF Finance Corporation priced a private offering of $500 million in aggregate principal amount of 0% senior unsecured exchangeable notes due 2032.
Pulse Biosciences, Inc. filed a Form 8-K on September 15, 2026, announcing completion of patient enrollment in its PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules.
Cabot Corporation filed a current report on Form 8-K on September 15, 2026, disclosing the Board of Directors' election of Steven J. Delahunt as interim Chief Financial Officer, effective October 1, 2026, as part of a broader management transition.
Origin Bancorp, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing that it has notified the New York Stock Exchange of its intention to voluntarily withdraw its common stock listing and transfer it to the Texas Stock Exchange, with the …
First Bancorp filed an 8-K with the SEC on September 15, 2026, disclosing that its board of directors declared a cash dividend of $0.24 per share on its common stock.
Bandwidth Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing that it plans to use investor presentation materials at various investor conferences during the third quarter of 2026.
Dream Finders Homes, Inc. filed a Form 8-K with the SEC on September 15, 2026, disclosing that it entered into Subscription Agreements with institutional investors on September 14, 2026, and completed a first closing of its newly-created Series B Convertible Preferred Stock offering, raising …
HealthStream, Inc. filed a Form 8-K on September 15, 2026, disclosing the completion on September 14, 2026, of a private securities transaction in which the company issued shares to a new investor and its CEO sold additional shares at $29.50 per share.
Jazz Pharmaceuticals Public Limited Company filed a Form 8-K with the SEC on September 15, 2026, disclosing the completion of its acquisition of Actio Biosciences, Inc.
Claritev Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on September 15, 2026, disclosing the appointment of Ben Letham as a Class I director and member of the Board's Risk Committee, effective September 14, 2026.